In addition, anakinra (Kineret), an IL‐1 receptor antagonist that blocks the biologic activity of IL‐1, has been confirmed to be safe to inject into the human body.25, 26 Thus, anakinra has been approved as a clinical drug for the treatment of symptoms of rheumatoid arthritis and hidradenitis suppurative.27, 28 In summary, our study found that IL‐1RA acted as a tumor suppressor in EC via regulation of the IL‐1α/VEGF signaling pathway; therefore, IL‐1RA might serve as a potential molecular target for EC treatments. This evidence concerns the gene VEGFA and hidradenitis.